Facoltà di scienze biomediche

Induction of potent neutralizing antibody responses by a designed protein nanoparticle accine for respiratory syncytial virus

Marcandalli, Jessica ; Fiala, Brooke ; Ols, Sebastian ; Perotti, Michela ; de van der Schueren, Willem ; Snijder, Joost ; Hodge, Edgar ; Benhaim, Mark ; Ravichandran, Rashmi ; Carter, Lauren ; Sheffler, Will ; Brunner, Livia ; Lawrenz, Maria ; Dubois, Patrice ; Lanzavecchia, Antonio ; Sallusto, Federica ; Lee, Kelly K. ; Veesler, David ; Correnti, Colin E. ; Stewart, Lance J. ; Baker, David ; Loré, Karin ; Perez, Laurent ; King, Neil P.

In: Cell, 2019, vol. 177, no. 6, p. 1420-1431.e17

Respiratory syncytial virus (RSV) is a worldwide public health concern for which no vaccine is available. Elucidation of the prefusion structure of the RSV F glycoprotein and its identification as the main target of neutralizing antibodies have provided new opportunities for development of an effective vaccine. Here, we describe the structure-based design of a self-assembling protein ... More

Add to personal list
    Summary
    Respiratory syncytial virus (RSV) is a worldwide public health concern for which no vaccine is available. Elucidation of the prefusion structure of the RSV F glycoprotein and its identification as the main target of neutralizing antibodies have provided new opportunities for development of an effective vaccine. Here, we describe the structure-based design of a self-assembling protein nanoparticle presenting a prefusion-stabilized variant of the F glycoprotein trimer (DS-Cav1) in a repetitive array on the nanoparticle exterior. The two-component nature of the nanoparticle scaffold enabled the production of highly ordered, monodisperse immunogens that display DS-Cav1 at controllable density. In mice and nonhuman primates, the full-valency nanoparticle immunogen displaying 20 DS-Cav1 trimers induced neutralizing antibody responses ∼10-fold higher than trimeric DS-Cav1. These results motivate continued development of this promising nanoparticle RSV vaccine candidate and establish computationally designed two-component nanoparticles as a robust and customizable platform for structure-based vaccine design.